Sponsored

Imugene’s (ASX: IMU) HER - Vaxx and CHECKVacc to feature at ESMO Congress

July 24, 2023 06:57 AM IST | By Sonal Goyal
 Imugene’s (ASX: IMU) HER - Vaxx and CHECKVacc to feature at ESMO Congress
Image source: Company PPT

Highlights

  • Imugene’s oncolytic virotherapy platform and B cell immunotherapy are to be presented at the ESMO Congress.
  • ESMO Congress is amongst the most influential oncology platforms globally.
  • The oncology event is to be held in Madrid during 20-24 October 2023.

ASX-listed clinical-stage immune-oncology company Imugene Limited (ASX: IMU) shared that its cancer therapy platforms HER - Vaxx and CHECKVacc will be featured at the ESMO (European Society for Medical Oncology) Congress. The event will take place in Madrid on 20-24 October 2023.

The ESMO Congress is one of the prominent oncology platforms for journalists, healthcare industry representatives, patient advocates, clinicians, researchers and journalists.

Imugene will feature in the following poster sessions:

HER - Vaxx is a B cell immunotherapy, and CHECKVacc is a CF33 oncolytic virotherapy being developed by Imugene.

Shares up ~4%

Following the update, the share price of IMU increased by 3.191% to trade at AU$0.097 per share at the time of writing on 24 July 2023.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

Sponsored Articles


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.